ABSTRACT:Recently, a number of inhibitors of the enzyme oxidosqualene cyclase (OSC; EC 5.4.99.7), a key enzyme in sterol biosynthesis, were shown to inhibit in mammalian cells the multiplication of Trypanosoma cruzi, the parasite agent of Chagas' disease. The gene coding for the OSC of T. cruzi has been cloned and expressed in Saccharomyces cerevisiae. The expression in yeast cells could be a safe and easy model for studying the activity and the selectivity of the potential inhibitors of T. cruzi OSC. Sterols are eukaryotic membrane components that are necessary to support cell growth and differentiation. Sterol biosynthesis is a well-established chemotherapeutic target in pathogenic eukaryotes, such as fungi (1,2). The final product of the sterol biosynthetic pathway in fungi is the 24-alkyl sterol ergosterol. Ergosterol or similar 24-alkyl sterols are also the final products of the sterol synthetic pathway of some pathogenic protozoa including Trypanosoma species. These organisms cannot completely substitute these sterols with the cholesterol biosynthesized in host mammalian cells and need to synthesize at least some of their own distinctive sterols (3-5). This dependence on sterols suggests that sterol biosynthesis inhibitors may be useful antiprotozoal drugs. The sterol biosynthetic pathway ( Fig. 1) offers many potential targets for therapeutic purposes. Many effective antifungal drugs already in use act by inhibiting different enzymes of sterol biosynthesis; the allylamine antifungal drug terbinafine inhibits squalene epoxidase (6), and azole drugs such as ketoconazole and itraconazole are inhibitors of lanosterol C 14 -demethylase (7). The activity of these inhibitors can be explained as a consequence either of depletion of the ergosterol or of accumulation of toxic intermediates or side products. In addition to the antifungal activity, some of these compounds
Acetyl-CoAwere shown to inhibit the growth of Trypanosoma and other kinetoplastid parasites (8). Kinetoplastid parasites have also been shown recently to be susceptible to inhibitors of squalene synthase (9,10) and oxidosqualene cyclase (11,12). The enzyme oxidosqualene cyclase (OSC; EC 5.4.99.7), which catalyzes the formation of the first cyclic precursor of sterols, is considered a good target for the inhibition of sterol biosynthesis in both humans and fungi. Many inhibitors, designed on the basis of the complex cyclization mechanism of OSC (13), are active on the enzyme and have been investigated as potential cholesterol-lowering or antifungal drugs (1,2,13). The recent crystallization of human OSC as a complex with the potent inhibitor RO48-8071 opens the way to new structurebased studies of the cyclization mechanism (14).We have designed and tested against mammalian and fungal OSC many acyclic substrate analogs modified either to mimic the high-energy carbocationic intermediates (compounds 1-3 of Fig. 2) or to bear reactive functions able to interact with the active site residues, as the methylidene (compounds 4-8), vinyl sulfide (compounds 9...